Creo Medical Group PLC Director/PDMR Shareholding (2870I)
August 07 2019 - 7:57AM
UK Regulatory
TIDMCREO
RNS Number : 2870I
Creo Medical Group PLC
07 August 2019
Creo Medical Group plc
("Creo" or the "Company")
Director / PDMR Shareholding
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
on 6 August 2019, Charles Spicer, Non-Executive Chairman, purchased
14,220 ordinary shares of GBP0.001 each in the capital of the
Company ("Ordinary Shares") via his Self-Invested Personal Pension
("SIPP") at a price of 140.64 pence per Ordinary Share.
Following this purchase, Charles Spicer holds 80,010 Ordinary
Shares in the Company, representing approximately 0.066% of the
Company's issued share capital.
The information below, set out in accordance with the
requirements of the MAR, provides further detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Charles Spicer
-------------------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------
a) Name Creo Medical Group plc
-------------------------------------- ---------------------------------------
b) LEI 213800H188ZDCWWXFA21
-------------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.001 each
financial instrument,
type of instrument
Identification code GB00BZ1BLL44
b) Nature of the transaction Purchase of shares via SIPP
-------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
-------------------- --------------
Price(s) Volume(s)
-------------------- --------------
140.64 pence 14,220
------------------------------------------------------------------- --------------
d) Aggregated information
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 6 August 2019
-------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange
-------------------------------------- ---------------------------------------
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Lianne Cawthorne Mob: +44 (0)7515 909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFEFTEIDIIA
(END) Dow Jones Newswires
August 07, 2019 08:57 ET (12:57 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2023 to Jul 2024